A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Gynecological Malignancies Clinical Trial

Official title:

A Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 for Injection in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06131450
• Other study ID #: BL-M07D1-203
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: February 29, 2024
• Est. completion date: December 2025

Study information

• Verified date: April 2024
• Source: Sichuan Baili Pharmaceutical Co., Ltd.
• Contact: Hai Zhu, PHD
• Phone: +8613980051002
• Email: zhuhai[@]baili-pharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-arm, open, multicenter, non-randomized phase Ib/II clinical study evaluating the efficacy and safety of BL-M07D1 for injection in patients with HER2-expressing recurrent or metastatic gynecologic malignancies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Sign the informed consent form voluntarily and follow the protocol requirements;

2. Female;

3. Age: =18 years old and =75 years old;

4. Expected survival time =3 months;

5. patients with recurrent or metastatic HER2-positive/low-expression gynecologic malignancies who have failed or are intolerant to standard treatment or who currently have no standard treatment;

6. The histopathology of gynecological malignant tumors should meet the following conditions: HER2 positive; Low expression of HER2;

7. Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;

8. At least one measurable lesion meeting the RECIST v1.1 definition was required;

9. ECOG score 0 or 1;

10. The toxicity of previous antineoplastic therapy has returned to = grade 1 defined by NCI-CTCAE v5.0;

11. No severe cardiac dysfunction, left ventricular ejection fraction =50%;

12. No blood transfusion, use of any cell growth factors and/or platelet-raising drugs were allowed within 14 days before screening, and the organ function level had to be acceptable;

13. Urinary protein =2+ or =1000mg/24h;

14. albumin =30 g/L;

15. Women who are likely to give birth must have negative serum/urine pregnancy within 7 days before treatment and must be non-lactating; All enrolled patients should have adequate contraception throughout the treatment cycle and for 6 months after the end of treatment.

Exclusion Criteria:

1. had received anti-tumor therapy before the first dose; Mitomycin and nitrosoureas; Oral fluorouracils; Palliative radiotherapy; Anti-tumor traditional Chinese medicine or Chinese patent medicine;

2. had received prior ADC drug therapy with camptothecin derivative (topoisomerase I inhibitor) as toxin;

3. had a history of serious cardiovascular and cerebrovascular diseases;

4. active autoimmune or inflammatory diseases;

5. Patients with other malignant tumors within 5 years before the first administration, except cured skin squamous cell carcinoma, basal cell carcinoma, superficial bladder cancer and prostate/cervix/breast cancer in situ;

6. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, and pulmonary embolism requiring medical intervention within 6 months before screening;

7. patients with massive or symptomatic effusions or poorly controlled effusions;

8. Hypertension poorly controlled by antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);

9. Current interstitial lung disease, drug-induced interstitial pneumonia, radiation pneumonitis requiring steroid therapy, or a history of these diseases;

10. patients with central nervous system (CNS) metastases and/or carcinomatous meningitis (meningeal metastases);

11. patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any ingredient of BL-M07D1;

12. patients received previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

13. HIVAb positive, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;

14. active infections requiring systemic therapy, such as severe pneumonia, bacteremia, sepsis, etc.;

15. had participated in another clinical trial within 4 weeks before the first dose;

16. pregnant or lactating women;

17. The investigator did not consider it appropriate to apply other criteria for participation in the trial.

Related Conditions & MeSH terms

• Gynecological Malignancies
• Neoplasms

Intervention

Drug:
• BL-M07D1
Administration by intravenous infusion

Locations

Country	Name	City	State
China	Cancer Hospital, Chinese Academy of Medical Sciences	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
Sichuan Baili Pharmaceutical Co., Ltd.	Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase Ib: Recommended Phase II Dose (RP2D)	The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M07D1.	Up to approximately 24 months
Primary	Phase II: Objective Response Rate (ORR)	ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.	Up to approximately 24 months
Secondary	Treatment-Emergent Adverse Event (TEAE)	TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M07D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1.	Up to approximately 24 months
Secondary	Phase Ib: Objective Response Rate (ORR)	ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.	Up to approximately 24 months
Secondary	Disease Control Rate (DCR)	The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD]).	Up to approximately 24 months
Secondary	Duration of Response (DOR)	The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.	Up to approximately 24 months
Secondary	Progression-free Survival (PFS)	The PFS is defined as the time from the participant's first dose of BL-M07D1 to the first date of either disease progression or death, whichever occurs first.	Up to approximately 24 months
Secondary	Cmax	Maximum serum concentration (Cmax) of BL-M07D1 will be investigated.	Up to approximately 24 months
Secondary	Tmax	Time to maximum serum concentration (Tmax) of BL-M07D1 will be investigated.	Up to approximately 24 months
Secondary	Ctrough	Ctrough is defined as the lowest serum concentration of BL-M07D1 prior to the next dose will be administered.	Up to approximately 24 months
Secondary	ADA (anti-drug antibody)	Frequency of anti-BL-M07D1 antibody (ADA) will be investigated.	Up to approximately 24 months